atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
The long-awaited NHS 10 Year Health Plan, unveiled today by Sir Keir Starmer, has set out a bold vision for reshaping health and care in England with community and the NHS App at its core to deliver for patients.
Health…
The founder and CEO of innovation coalition the Health Tech Alliance talks prioritising patient benefit over profit and how SMEs and startups better engage with the NHS.
Read more here.